|
Age at vaccination (years); median (min, p25, p75, max)
|
60 (26, 54, 69, 76)
|
|
Sex (# males/# females)
|
19/21
|
|
Delay between vaccination and transplantation (months); median (min, p25, p75, max)
|
31 (6, 14, 42, 57)
|
|
Donor type (# MSD/MUD/ MMUD/Haplo)
|
8/26/1/5
|
|
Donor age at transplantation (years); median (min, p25, p75, max)
|
34 (18, 23, 46, 62)
|
|
Conditioning regimen (# patients)
| |
|
Fludarabine + 2 Gy TBI
|
5
|
|
Fludarabine + Melphalan
|
18
|
|
Fludarabine + busulfan
|
4
|
|
Cyclophosphamide + 12 Gy TBI
|
6
|
|
Thiotepa + busulfan + fludarabine
|
2
|
|
Sequential
|
3
|
|
Fludarabine + Cyclophosphamide + 2 or 4 Gy TBI
|
2
|
|
ATG (# yes/no)
|
29/11
|
|
PTCY (# yes/no)
|
6 /34
|
|
Chronic GVHD
| |
|
Never/only mild
|
29
|
|
Prior moderate/severe solved*
|
2
|
|
Ongoing moderate/severe
|
9
|
|
Rituximab (none or ≥ 2yrs, ≥ 1 but < 2 yrs, > 6 months but < 1 yr), # of patients
|
28, 5, 7
|
|
Systemic immunosuppression at inclusion
| |
|
None
|
26
|
|
Tacrolimus
|
5
|
|
Photopheresis
|
1
|
|
Photopheresis + mPDN < 32 mg/day
|
1
|
|
MMF
|
1
|
|
MMF + mPDN < 32 mg/day
|
1
|
|
Sirolimus
|
1
|
|
Sirolimus + mPDN < 32 mg/day
|
2
|
|
Photopheresis + ruxolitinib
|
2
|
